XML 67 R51.htm IDEA: XBRL DOCUMENT v3.25.1
Material Agreements (Details) - USD ($)
$ in Thousands
3 Months Ended 53 Months Ended
Mar. 27, 2023
Mar. 02, 2023
Oct. 26, 2022
Sep. 26, 2022
Nov. 03, 2020
Oct. 23, 2020
Apr. 01, 2016
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 03, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Royalties related to the sale of future revenue               $ 8,720 $ 12,053    
Assertio Holdings, Inc                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Royalties related to the sale of future revenue     $ 6,000                
Proceeds from collaborators     $ 9,000                
Manufacture and supply revenue                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Royalties related to the sale of future revenue               7,193 10,518    
License and royalty revenue                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Royalties related to the sale of future revenue               $ 790 $ 1,132    
Commercial exploitation agreement with Indivior                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
License agreement term               7 years      
Automatic renewal period of agreement   1 year           1 year      
License agreement with Sunovion Pharmaceuticals, Inc.                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Aggregate payment           $ 22,000          
License agreement with Sunovion Pharmaceuticals, Inc. upfront                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Aggregate payment           5,000          
License agreement with Sunovion Pharmaceuticals, Inc milestones                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Aggregate payment           $ 17,000          
License agreement with Sunovion Pharmaceuticals, Inc milestones | License and royalty revenue                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Royalties related to the sale of future revenue             $ 4,000        
MAM Pangolin Royalty , LLC | Monetization Agreement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Additional proceeds from sale of future revenue         $ 10,000            
Proceeds from sale of future revenue         40,000         $ 50,000  
Proceeds from debt, contingent on additional milestones         75,000            
MAM Pangolin Royalty , LLC | Maximum                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Proceeds from sale of future revenue         $ 125,000            
Haisco Pharmaceutical Group Co., Ltd, upfront payment                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Receivable                     $ 7,000
License & Supply Agreement | Atnahs Pharma UK Limited                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Proceeds from sale of future revenue       $ 3,500              
Atnahs Pharma UK Limited, Amended Agreement | License & Supply Agreement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Proceeds from sale of future revenue $ 2,000